Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard Oncology Care Clear all
Recruiting Not applicable Interventional

Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer

NCT05947695
View directory record Official record
Conditions
Solid Tumor, Adult, Metastasis
Interventions
Palliative and Survivorship Care Model
Behavioral
Lead sponsor
Good Samaritan Hospital Medical Center, New York
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
West Islip, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 2, 2026, 4:19 AM EDT
Completed Not applicable Interventional Results available

Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors

NCT04075734
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Managing Your Health: Self-Management + Peer Mentoring
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 29 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 2, 2026, 4:19 AM EDT
Not yet recruiting Phase 2 Interventional

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

NCT07619365
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Trastuzumab deruxtecan, Lovastatin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

NCT01966471
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
50
States / cities
Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Not applicable Interventional

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT05287451
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer
Interventions
RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 2, 2026, 4:19 AM EDT
Completed Not applicable Interventional

Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer

NCT04493034
View directory record Official record
Conditions
Breast Cancer
Interventions
Art Therapy, Music Therapy
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Early Phase 1 Interventional

Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

NCT03594630
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Chemotherapy, Patient Observation, Questionnaire Administration, Resection of Rectum
Drug · Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Phase 2 Interventional

Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy

NCT07201519
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma
Interventions
Hepatic Artery Infusion Pump (HAIP), Standard Treatment, Community Treatment, Systemic Chemotherapy Standard of Care, Standard Of Care targeting driver mutations
Device · Procedure · Drug
Lead sponsor
Michael J Cavnar, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Completed No phase listed Observational

Psychosocial Support for Cancer Patients

NCT00133965
View directory record Official record
Conditions
Cancer
Interventions
Dignity Psychotherapy, Supportive Psychotherapy, Standard Palliative Care
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Oct 2, 2026, 4:19 AM EDT
Active, not recruiting Phase 3 Interventional

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

NCT02215265
View directory record Official record
Conditions
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Interventions
Cisplatin, Postoperative radiotherapy
Drug · Radiation
Lead sponsor
Lisette Nixon
Government
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
3
States / cities
Redwood City, California • Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 2, 2026, 4:19 AM EDT
Not yet recruiting Phase 2 Interventional

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

NCT07770100
View directory record Official record
Conditions
Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions
Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab
Radiation · Drug
Lead sponsor
Mark Bernard
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Not applicable Interventional

Improving Health Literacy in African-American Prostate Cancer Patients

NCT03322891
View directory record Official record
Conditions
Prostate Cancer
Interventions
Educational Supplement, Standard Practice Education
Other
Lead sponsor
Emory University
Other
Eligibility
25 Years to 100 Years · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Not applicable Interventional

SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

NCT06896474
View directory record Official record
Conditions
Breast Cancer
Interventions
Shared Decision-Making Training and Decision Aid
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
11
States / cities
Los Angeles, California • Boston, Massachusetts • Burlington, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Terminated Phase 1 Interventional

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05341349
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic Radiosurgery, Tumor Treating Fields Therapy
Biological · Radiation · Procedure
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
Drug · Combination Product
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Active, not recruiting Phase 3 Interventional

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
JDQ443, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

NCT06412510
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
Interventions
Prehabilitation
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

NCT02734290
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Pembrolizumab, Paclitaxel, Capecitabine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 2, 2026, 4:19 AM EDT
Terminated Early Phase 1 Interventional

MRI Laryngeal Imaging With a Surface Coil

NCT00965003
View directory record Official record
Conditions
Laryngeal Neoplasms, Head and Neck Cancers, Larynx Cancer
Interventions
MRI scan
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 2, 2026, 4:19 AM EDT
Completed Phase 1 Interventional

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

NCT00849550
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Cancer
Interventions
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Harvey, Illinois • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Oct 2, 2026, 4:19 AM EDT
Completed Not applicable Interventional

Complete Decongestive Therapy on Head and Neck Lymphedema

NCT04045860
View directory record Official record
Conditions
Lymphedema of Face, Secondary Lymphedema
Interventions
Complete Decongestive Therapy, Observation
Procedure · Other
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 2, 2026, 4:19 AM EDT
Terminated Phase 1 Interventional

Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer

NCT01790035
View directory record Official record
Conditions
Gastrointestinal Neoplasms
Interventions
LGG, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 2, 2026, 4:19 AM EDT